Algeta schedules First Quarter 2010 Presentation
(Thomson Reuters ONE) -
Oslo, Norway, 3 May 2010 - Algeta ASA (OSE: ALGETA), the focused oncology
company, will announce its first quarter 2010 results on Friday, 7 May 2010. A
presentation to investors, analysts and the press will take place in Oslo at
09:45 CET. Algeta's President and CEO Andrew Kay and CFO Øystein Soug will
present.
The presentation will also be webcast live and can be accessed from
www.algeta.com/webcast
submitted live during the presentation.
The presentation will take place at 09:45 CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
Norway.
The results report and the presentation will be made available on www.algeta.com
###
For further information, please contact
+47 23 00 67 42 / +47 484 01 360 (mob)
Andrew Kay, CEO +47 23 00 79 84 / +47 906 56 525 (mob)
Øystein Soug, CFO post(at)algeta.com
Dr Mark Swallow / David Dible / Helena +44 (0) 207 638 9571
Galilee
mark.swallow(at)citigatedr.co.uk
Citigate Dewe Rogerson
About Algeta
Algeta is a focused oncology company developing novel targeted therapies for
patients with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (based on radium-223) is a first-in-class,
highly targeted alpha-pharmaceutical under clinical evaluation to improve
survival in patients with bone metastases from advanced cancer. Its localized
action helps preserve the surrounding healthy tissue thereby limiting
side-effects.
The development of bone metastases represents a serious development for cancer
patients as they are associated with a dramatic decline in patient health and
quality of life, ultimately leading to death. Bone metastases represent a major
unmet medical need, occurring in up to 90% of certain late-stage cancers, e.g.
prostate, breast and lung.
Alpharadin is partnered with Bayer Schering Pharma AG, a major pharmaceutical
company, and is in a global phase III clinical trial (ALSYMPCA) to treat bone
metastases resulting from castration-resistant (hormone-refractory) prostate
cancer. Alpharadin is also under investigation in phase II clinical trials as a
potential new treatment for bone metastases in endocrine resistant breast cancer
patients.
Algeta also aims to develop a future pipeline of tumor-targeting
alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227,
through selective in-licensing and/or acquiring innovative technologies and
tumor-targeting molecules.
The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta
listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. There are a number of
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
###
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1411011]
Press release: http://hugin.info/134655/R/1411011/363346.pdf
Unternehmensinformation / Kurzprofil:
Datum: 03.05.2010 - 10:00 Uhr
Sprache: Deutsch
News-ID 20141
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta schedules First Quarter 2010 Presentation"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
